Feasibility of a digital therapeutic for experiential negative symptoms of schizophrenia: results from an exploratory study.

Haig Goenjian¹, Abhishek Pratap², Cassandra Snipes³, Brendan D Hare³, Joshua T Kantrowitz⁴, Tshekedi Dennis⁵, Wakelin McNeel⁶, Eehwa Ung³, Olya Besedina³, Alankar Gupta³, Tim Campellone³, Mariya Petrova³, Sergio Perocco⁷, Uma Vaidyanathan⁷, Shaheen E Lakhan³, Cornelia Dorner-Ciossek⁸

¹CenExel CNS, Garden Grove and Los Alamitos, Los Alamitos, CA, USA.

²Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA. abhishek.pratap@boehringer-ingelheim.com.

³Click Therapeutics, Inc., New York, NY, USA.

⁴Columbia University Department of Psychiatry and New York State Psychiatric Institute (NYSPI), New York, NY, USA.

⁵Velocity Clinical Research, Santa Ana, CA, USA.

⁶BHC Alhambra Hospital, Rosemead, CA, USA.

⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.

⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany. cornelia.dorner-ciossek@boehringer-ingelheim.com.

PubMed PMC DOI PDF

Abstract

Experiential negative symptoms (ENS) of schizophrenia, such as asociality, anhedonia, and avolition, are associated with poor outcomes, yet no FDA-approved pharmacotherapies currently exist specifically to target these symptoms. With the increasing use of smartphones, evidence-based digital interventions delivered by prescription digital therapeutics (DTx) may present an opportunity to address the…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.